Conference abstract · 6 Oct 2017
Conference abstractPublished 28 Sep 2018
Metabolic stability in vitro assay of new drug candidates for Tuberculosis
Sao Paulo State University, Brazil
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: The development of new drugs is a complex process, with only 0.027% of newly synthesized molecules being approved by regulatory agencies. Inadequate pharmacokinetic properties and toxicity are responsible for half of the failures in this process and the in vitro screening of new molecules assists in the selection of the best candidates and to understand the results of in the in vivo studies. In the metabolic stability assay, the molecules are submitted to a microsomal system to evaluate their degradation by the microsomal enzymes. Considering that Tuberculosis is still responsible for millions of deaths and cases of bacterial resistance to the drugs used in the treatment only increase, esters of pyrazinoic acid, the active metabolite of pyrazinamide, have been developed as a novel alternative for this treatment, and the present work aimed to evaluate the metabolic stability of POAEt POAEtPOA and POAMe. Methodology: The compounds were incubated with 0.5mg/mL rat microsome for up to 120 minutes in buffer, with and without NADPH regenerating system. They were tested in concentrations of 2, 5 and 10μM. The samples were quantified by UHPLC, with previously developed methods. Diclofenac was used as a control of the system. Results: The control was adequate, indicating the system operation, showing a half-life of 33 minutes. The quantification was not possible in the 2μM, while the concentrations of 5 and 10μM presented the same profile, thus, the concentration of 5μM was chosen to perform the experiment. The compounds showed no decay in any of the situations referred to it, making it impossible to calculate the elimination half-life, and therefore the extrapolated clearance. Conclusion: It was observed that the three molecules were stable in this system and there was no activity of the microsomal enzymes on these compounds.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 2019
Adverse events in multi-drug resistant tuberculosis patients registered at DOTS-Plus site, AIIMS, New Delhi
Mini review · 29 Mar 2018
VXc-486 potent drug: A new drug approach in tuberculosis treatment.
Conference abstract · 28 Nov 2016
The cell envelope of Mycobacterium tuberculosis and new drug discovery against tuberculosis
Conference abstract
Discovery of WecA inhibitors for development of new TB drugs for dormant Mycobacterium tuberculosis infections
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectInfectious Diseases
- SubjectPharmaceutical Sciences
- SubjectPulmonology & Respiratory
- BylineArticles whose byline prints “Taisa Busaranho Franchin”
